2019 Speakers

Tudor Arvinte studied physics at University of Jassy, Romania, and received his Ph.D. in biophysics from University of Düsseldorf, Germany. He held numerous research positions in Europe and the USA at: Max-Planck Institute, Germany; C.N.R.S., France; Cornell University, New York; Texas A&M...

Carla C. Baan, PhD, is professor and head of the Nephrology & Transplantation Laboratory at Erasmus Medical Center, University Hospital Rotterdam, The Netherlands. Dr Baan obtained her doctorate from Erasmus University, The Netherlands.Her position involves the supervision of doctorate research ...

A Medical professional with specialization in M.D. Clinical Pharmacology with 18 years of Pharma/Biopharma experience; Currently working as Vice President & Head– Medical, Clinical & Regulatory affairs for Wockhardt , Mumbai ; Earlier worked for Intas Pharma Ltd (15 years ) & Alembic (2 ...

Dr. Bateman is currently Scientific Associate Vice President and the Scientific Lead for Bioanalysis in the Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism at Merck & Co. where he has worked for over 21 years.  He is the co-founder of the Merck Smart Trials initiative aimed ...

Dr. Beck has contributed to the R&D of anticancer mAbs (dalotuzumab/IGF-1R with Merck, h224G11/cMet with Abbott, h515H7/CXCR4, h6F4/JAM-A), vaccines and peptides. He is inventor on 16 patents and author of more than 90 publications (editorials, features, research papers, invited reviews and...

Dr. Roger R. Beerli, PhD (CSO, NBE-Therapeutics AG) has over 15 years of experience in discovery, engineering and preclinical development of therapeutic antibodies. Previously he has led R&D activities related to therapeutic antibody development at Cytos, Switzerland, and later at...

Stephen Beers joined the University of Southampton, Faculty of Medicine in 2002. His research group is interested in how antibodies work to result in tumour regression. Their research is currently focused on how host factors such as the tumour microenvironment and obesity/nutrition affect cancer...

Mehdi Benchoufi is an Assistant Professor in Epidemiology in Clinical Epidemiology Center, at Hôtel Dieu Hospital, with Pure Mathematics and Computer Science background. His main interests are on the augmentation of healthcare by new technologies, and Open Science as an inclusive tool to improve...

Guillaume began his studies at the High Preparatory School in Biology in France, from which he holds MSc in Biotechnology in 2012. He worked four years for Novartis and UCB where he worked at the Center of Expertise for Biologics in Switzerland. Currently working as a Marie Curie Early stage...

Alain Bindels is an experienced Design Thinking facilitator, who leads an Innovation task force at Roche, supporting different business units to adopt innovation. He is interested in patient centric design of the healthcare industry, using new available technologies. He is applying the Design...

2016 PhD "Optimization of recombinant protein expression in insect cells" at the Helmholtz Center for Infection Research (Braunschweig, Germany)10.2016-09.2018 Head of the recombinant protein expression facility at the Rudolf Virchow Centre (Würzburg, Germany)since 10.2018 Habilitation at ...

A physician by training and an expert in immunobiology and drug development, Ezio Bonvini is the Senior Vice President of Research and Chief Scientific Officer at MacroGenics, Inc., which he joined in 2003 after a career at the National Cancer Institute, NIH, and the Center for Biologics...

Patrick Bulau is principal scientist leading a team performing physico-chemical analyses with special focus on mass spectrometric technologies at Roche Pharma Technical Development in Penzberg, Germany. In addition to his responsibility for the analytics of drug substance development products he is ...

Dr Brian Champion is Chief Scientific Officer and member of the Executive Management Team at PsiOxus Therapeutics Ltd, Oxford, UK where he is leading the scientific team in the development of novel oncolytic virus-based, Tumor-Specific Immunogene (T-SIGn) therapies for the treatment of cancer.   He ...

Dr Vijay Chudasama (VC) is a Reader in the Chemistry department at University College London. He has won multiple prestigious prizes and awards (departmental, faculty, national and international) throughout his academic career such as the UCL Faculty of Mathematical and Physical Sciences Medal...

Professor Vladka Čurin Šerbec is a Head of R&D at the Blood Transfusion Centre of Slovenia and Professor at the Medical Faculty, University of Ljubljana. She finished her studies at the Faculty of Natural Sciences at the University of Ljubljana (BScChem, MScBiochem and PhD) and spent her...

I received a Engineer & Master degree in Antibody and Cell Engineering from Reims University in 2004.I have ~15 years of relevant industrial experience: Sanofi (2006-present), Centelion formerly Gencell fully owned by Sanofi (2004-2006). My accomplishments in antibody drug development include...

Dr. Dahan completed his PhD in Molecular Immunology at the Technion in 2010. He served as a postdoctoral fellow in Cancer Immunology at the Laboratory of Prof. Jeffrey Ravetch at Rockefeller University in New York from 2013 until joining the faculty of the Weizmann Institute of Science in...

Annick has over 15 years of experience in both pharma and academia in Australia, the USA, UK, Belgium and the Netherlands. She was trained as a neuroscientist (University of Amsterdam, NL) and acquired her PhD in Pharmacology at Utrecht University (NL). Her experience in assay development started...

Dr. Ruud de Wildt has more than 20 years of experience within the Biotech and Biopharmaceutical industry. His teams have delivered many therapeutic candidate molecules across several therapeutic areas including oncology, respiratory, infectious diseases and the immunology field. This includes...

John leads Amgen’s Biologic Discovery function responsible for identifying large molecule therapeutic candidates in collaboration with all Amgen Therapeutic Areas, including the discovery of fully human antibody therapeutics using the company’s proprietary platform technology. John joined Amgen in...

Surjit Dixit, Ph.D., is the Chief Technology Officer of Zymeworks Inc. His responsibilities include the advancement of the ZymeCAD™ platform for computer aided therapeutic protein optimization and its application towards the development of novel molecular platforms and tailored therapeutic...

Before joining the EPO, Dr. Domingues completed a PhD degree in Protein Engineering at the European Molecular Biology Laboratory in Heidelberg in collaboration with the University of Utrecht, followed by post-doctoral work. She joined the EPO in October 2000 and worked as a Patent Examiner in the...

As R&D Director of GEROPHARM Roman establishing product development of the company’s portfolio.Joined GEROPHARM as a head of clinical trials department in Oct 2016. Successfully performed several clinical trials including hyperinsulinemic euglycemic clamps and bioequivalence, Phase III...

Dr. Birgit Dreier has been Senior Scientist in the group of Prof. Dr. A. Plückthun at the Department of Biochemistry, University of Zurich, for more than 10 years and is responsible for the organization, optimization and selection of DARPins (Designed Ankyrin Repeat Proteins) and other scaffold...

Stefan Ewert, Ph.D. joined Novartis in 2004 and holds the position of a Senior Investigator within the NIBR Biologics Center. He is responsible for antibody phage display selections done in Basel. Before joining Novartis he was instrumental in developing ESBATech’s scFv-based key technology. During ...

Figini has been involved in antibody production, characterization and engineering from the beginning of her career starting with the classic hybridoma technology and chimerization up to isolation of human antibodies from phage display library a revolutionary technology discovered in the early...

Jonny Finlay is the CEO of UltraHuman, an antibody drug discovery biotech in the UK that is developing a series of therapeutics for inflammation and oncology. Prior to co-founding UltraHuman, Jonny led research teams in Biologics Discovery at Pfizer and Wyeth, and carried out postdoctoral research...

Nicolas Fischer obtained a PhD in Biology from the Department of Molecular Biology University of Geneva on the structure and function of photosynthetic complexes. As a postdoctoral fellow he joined the Group of Sir Greg Winter at the MRC Department of Molecular Biology in Cambridge UK to study...

Patrick Garidel is currently employed as Head of Pharmaceutical and Protein Science at Boehringer Ingelheim Pharma GmbH & Co. KG. His activities are focused on the development biologics from the downstream process to drug product (liquid and solid formulations, freeze-drying). His expertise...

Ulf Grawunder is CEO of NBE-Therapeutics, a Swiss Biotech company that he founded in 2012 and which focuses on the development of "next-generation" antibody-drug conjugates for cancer therapy. Prior to that, Ulf had co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering...

Keno Gutierrez, PhD, MBA, joined the Healthcare team of Merck Ventures as an Investment Director in 2017. Previously, he worked at Omega Funds, where he invested in public and private healthcare companies, participating in direct investments and secondaries. Before joining Omega in 2014, Keno was...

Eric Halioua is a serial entrepreneur with strong managerial, technological, fund-raising and deal-making experience. Eric Halioua is President and CEO of PDC*line Pharma a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid...

Guy joined Isogenica as CSO in 2016. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development. At Isogenica, he leads the internal technology and product development, as well as drive scientific interactions...

Oliver Hill joined Apogenix in March 2006. He is an expert for protein engineering and protein expression technologies. Prior to his position at Apogenix, he headed the protein expression and purification group at Graffinity Pharmaceutical Design GmbH (Heidelberg, Germany) from 1999 to 2006. At...

Dr. Yue Huang graduated from Beijing Medical University, China, then obtained his PhD from University of Minnesota, USA.  He also completed an executive MBA from Swiss Business School (SBS) in Switzerland. Dr. Huang has 17+ years of pharmaceutical industry experience, with specialties in the...

Dr. Yue Huang graduated from Beijing Medical University, China, then obtained his PhD from University of Minnesota, USA.  He also completed an executive MBA from Swiss Business School (SBS) in Switzerland. Dr. Huang has 17+ years of pharmaceutical industry experience, with specialties in the...

An innovation, multi award-winning Clinical Operations and Consulting Expert with extensive experience and skills gained from international global assignments.  A blockchain advocate and patient engagement thought leader with over 17 years in the NHS on commission by the DOH and in Industry...

Prior to co-founding medicxi, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003.  Kevin spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He is currently...

Colette has been part of Crescendo Biologics since 2012. She is responsible for the proprietary mouse platform and early discovery activities in Crescendo’s Humabody discovery pipeline.  Colette joined Crescendo from MedImmune where she was in the Department of Antibody Discovery and Protein...

Having spent nearly a decade in clinical research working for the National Health Service, Academia, the Institute for Health Research an now Pharma I have gained a vast knowledge of many of the sectors providing input into clinical trials within the UK. I have a lot of experience in managing study ...

Dr. Hélène Kaplon completed a PharmD at the University of Lille in 2014. Since 2011, she has co-authored Acthera, a guide of Therapeutic Antibodies approved in the European Union written for pharmacy students and pursued her career in the immuno-oncology field. Beginning 2015, she started a PhD in...

Project manager of the International Clinical Trials Registry Platform (ICTRP) in the World Health Organization since 2011, expert in clinical trials database design, clinical trials registration & results and ethics committees information systems. Member of several international working groups ...

Andreas is co-founded Anaveon in April 2018, and previously was the Director of Autoimmunity, Transplantation & Inflammation, Novartis Institutes of  Biomedical Research, Basel Big Pharma experience in the discovery and development of immunomodulating drugs (26 years) Extensive BD&L...

Christian Klein, Distinguished Scientist is Head of Oncology Programs at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and preclinical development of antibody based cancer immunotherapies and bispecific...

Dr. Jiri Kovarik has more than 15 years of experience in drug R&D at the Novartis Institutes for Biomedical Research with focus on the generation of therapeutic antibodies for the treatment of inflammatory/auto-immune diseases. Before working in industry, his scientific activities included the...

Dr. Anne Månsson Kvarnhammar earned her PhD 2009 at Lund University, Sweden, working on the immune response in allergic rhinitis. This area was further pursued during a postdoc position at Karolinska institutet. In 2012, Dr. Kvarnhammar joined Novo Nordisk, Denmark, working with developing models...

Since 2000, Kai has been a pioneer in patient-facing solutions for clinical trials working with young innovative technology companies. In 2012, Kai co-founded eClinicalHealth, the developers of the Clinpal remote clinical trial platform. Through his involvement in technical, operational and...

Heinz Läubli is a physician scientist with clinical training and a specialisation in Medical Oncology. He is a senior attending physician at the University Hospital in Basel, Head of a clinical research group and Head of Glycobiology Research in the Cancer Immunology Laboratory in Basel. His...

Associate Professor Andreas Hougaard Laustsen heads the Tropical Pharmacology Lab at the Department of Biotechnology and Biomedicine, Technical University of Denmark. He is specialized in antibody discovery, toxinology, antivenom, and neglected tropical diseases. Andreas is an Advisor to the WHO’s...

Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at Paris-Saclay University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 ...

Dr. Li is a Senior Director of Clinical Pharmacology at Shire.  She has nearly 20 years of industrial experience in clinical development for small molecules, RNA based therapies and biologics, including monoclonal antibodies and enzyme replacement therapies.  Prior to joining Shire in June...

Chris Lloyd is a Senior Scientist working in the Antibody Discovery and Protein Engineering (ADPE) group at MedImmune, Cambridge UK. He has over 15 years’ experience in the field of antibody engineering at MedImmune (and previously CAT), currently with an active interest in bispecific antibodies...

John Löfblom is associate professor at KTH Royal Institute of Technology. His current research focus is on method development for directed evolution of affinity proteins, proteases and aggregation inhibitors as well as engineering of small affinity proteins into multimeric formats for new modes of...

Dr. Mamula’s interests are in investigating the early events involved with breaking immune tolerance to self proteins, both in autoimmune disease and in tumor biology.  Overall, it is the goal of Dr. Mamula’s laboratory to understand the mechanisms that may shift the balance toward the initiation...

Andrea Marschall studied Molecular Biotechnology at Heidelberg University, gained a PhD in Stefan Dübel's lab on targeting antibodies into living cells, continuing with Postdoctoral research at the Helmholtz Centre for Infection Research in Braunschweig (Germany) and at Brandeis University in...

Rita Martello received her degrees in pharmaceutical chemistry from University of Bologna, Italy and her PhD in Biology from University of Konstanz, Germany. Rita gained experience in LC-MS/MS based proteomics as postdoctoral fellow at the Novo Nordisk Foundation Center for Protein Research in...

Dr. Masternak is the Head of Biology at Novimmune. Since joining Novimmune in 2002, he was involved in monoclonal antibody development in the field of inflammation and autoimmunity. He currently oversees immuno-oncology bispecific antibody discovery. Prior to Novimmune, Dr. Masternak worked as a...

Ivana is a certified MD who has spent over a decade in clinical research, gaining experience in various country, regional and global job roles at MSD. She holds a position of Global Operations Lead – Agreements, as well as the process ownership over site ready support with an accent on the...

Lamine is SVP & Head of Glenmark Biotherapeutics. Prior to joining Glenmark, Lamine held several leadership positions in the USA at Boehringer Ingelheim, Genomics Institute of Novartis Research Foundation (GNF), Novartis Vaccines and Centocor (Janssen) where he led and advanced several...

Christoph joined the European Molecular Biology Laboratory in Heidelberg, Germany, as a Principal Investigator in 2010, focusing on microfluidic technology for HTS and genomics. His lab is particularly interested in the development of droplet-based microfluidics for cell-based screens. Christoph is ...

Derek Mason worked as a process engineer in Denver, Colorado for 3 years before moving to Basel, Switzerland in 2015. Currently, he is finishing his PhD in the Laboratory for Systems and Synthetic Immunology at ETH Zurich’s Department of Biosystems Science and Engineering. Intrigued by recent...

Melissa is an Operational Intelligence Leader at F. Hoffmann - La Roche in Basel, where she supports recruitment and retention strategies in late stage development.  Her speciality has been helping teams build Recruitment and Retention strategies by implementing learnings around the patient’s...

Isabelle Naëije has a Master in Sciences degree in bio-engineering (Free University of Brussels, Belgium). Her thesis was devoted to the study of the protein MxiC in the regulation of the type III secretion system of Shigella flexneri. She works for Novartis Pharma AG, Basel, Switzerland. She is an ...

Dario Neri was born in Rome on 1 May 1963.. He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral...

Johan Nilvebrant received his PhD in 2012 at the Royal Institute of Technology, Stockholm, Sweden. He was a postdoc with Sachdev Sidhu at the University of Toronto where he worked on new single-domain antibody library designs and ligand-mimicking antibodies. His current research focuses on protein- ...

Ahuva Nissim graduated in Molecular Immunology in Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period she developed a phage display semi-synthetic human antibody library which has...

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug...

Tanja holds a PhD in Neurosciences from the University of Montréal (Canada). She then moved to Paris to pursue her research on metalloproteases as drug targets in academia before joining Pharmaleads in 2006 as Head of Biochemistry, characterizing metalloprotease and inhibitor activity in vitro and...

Richard Peck studied medicine in the USA and obtained a Doctor of Philosophy from the University of Tennessee. Following a Post-Doc at the Biozentrum of the University of Basel (medical virology, molecular biology), he was employed by F. Hoffmann LaRoche, Basel as International Regulatory Affairs...

Thomas Pillow received his Ph.D from Stanford University in organic chemistry under the direction of Professor Paul Wender. Upon graduation he moved to Genentech in 2009 where he is currently a senior scientist in the discovery chemistry department leading Genentech’s effort on antibody-drug...

Dr. Anne Poupon is Senior Scientist at the CNRS, heading the group Biology and Bioinformatics of Signalling Systems. After MS degrees in Biochemistry and in Mathematics, she has obtained a PhD thesis on the conservation of hydrophobicity in globular proteins. Since then she has been developing...

Christophe is responsible for directing and advancing the development of Oncorus’ next generation oncolytic viruses. An industry veteran, Christophe has nearly two decades drug discovery experience in immuno-oncology and a successful track record of building portfolio from target identification...

Following studies in molecular biology and biochemistry at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, Dr. Roesli performed his PhD thesis in the lab of Prof. Dario Neri at the same university. After the subsequent PostDoc period, he led his own research group on...

Michelle Rosenzwajg is at the head of the immunomonitoring team of the Clinical Investigation Center in Biotherapy. She is involved in translational research towards a better understanding of immunopathologies and the development from bench to bedside of immunotherapies in the field of cancer and...

Karsten Roth leads the clinical development and pharmacovigilance teams at Mundipharma-Biologics, former Cinfa Biotech. He is responsible for the development and implementation of preclinical, clinical and post-approval clinical activities and oversees the pharmacovigilance activities at...

Jack earned his Bachelor’s degree in Chemistry from Pomona College in 2000 and his Ph.D. in Chemistry from the University of Wisconsin – Madison in 2006.  His graduate work focused on the development of non-natural, oligomeric (beta-peptide) inhibitors of protein-protein interactions, leading to...

Dr Matthieu P Schapranow received a PhD in Software Engineering from University of Potsdam in Germany in 2012. He also received BSc and MSc degrees in Software Engineering, in 2006 and 2008, respectively from the Hasso Plattner Institute (HPI). Currently, he is Program Manager E-Health at the HPI...

Karoline W. Schjetne holds a PhD from Institute of Immunology, University of Oslo, followed by a postdoctoral scholarship where she also hospitalized as visiting researcher at Harvard Medical School. Karoline has worked in both biotech and big pharma industry within the area of immunotherapy and...

Dr Nabila SEDDIKI is a Senior Lecturer at the Paris-Est Créteil University (UPEC). She holds an INSERM “Chaire d’Excellence en Immunologie et Maladies Infectieuses”. She joined the Vaccine Research Institute (Créteil, France) end of 2010. Before that she was a Research Fellow at the Centenary...

Armin Sepp is Scientific Leader and GSK Associate Fellow at the Systems Modeling and Translational Biology group of GlaxoSmithKline where he is providing early stage project support for biotherapeutic projects covering mAbs, antibody fragments as well as cell and gene therapy products. His...

Oliver Seifert holds a PhD in Molecular Biology from the University of Stuttgart and he is a Post-Doc at the Institute of Cell Biology and Immunology based at the University of Stuttgart, Germany. Research interests focus on the design and development of multivalent and multispecific antibody...

Dr. Arne Skerra is Full Professor at the Technical University of Munich, Germany, where he heads the Institute of Biological Chemistry. He holds a Diplom degree in Chemistry from the Technical University of Darmstadt and a PhD in Biochemistry from the Ludwig-Maximilians-University Munich. After...

Alan Smith, is currently the Executive Vice President Technical Operations at Bellicum Pharmaceuticals. He has broad experience in the cell therapy area with over 30 years working in various senior management roles in research and development, manufacturing and quality in cell and gene therapy...

Dr. Spycher is a PSI Founder Fellow at the Paul Scherrer Institute (PSI) Villigen (Switzerland) working on the site-specific modification of native antibodies. He is a co-founder of the PSI spin-off Araris Biotech AG, incorporated in January 2019, that is focused on ADCs and advancing the newly...

Daniel performed his undergraduate studies at the ETH Zürich and at the Imperial College London. During his PhD studies at the University of Zurich with Prof. Dr. Andreas Plückthun, Daniel established a novel in vitro selection system enabling the efficient selection of DARPin molecules on complex...

Anke is a Senior Researcher in Molecular Design Sciences/Integrated Drug Discovery  at Sanofi R&D providing scientific project support for drug discovery on a broad range of target proteins in the fields of small molecules and biotherapeutics. Anke is profoundly motivated by the human and by...

Stenner Frank, Prof. Dr., M.D.Since 12/2016 Head of the Hematology-Oncology Tumor Center (ZHO)/ BaselSince 06/2012 Senior Physician of Oncology at the University Hospital Basel, Switzerland11/2011-05/2012 Senior Physician of Oncology at the University Hospital Zurich11/2005-11/2011 Attending...

Dr. Pawel Stocki – Director of Research at Ossianix. At Ossianix we are utilising single domain shark antibody fragments to tackle the problem of therapeutic biologics delivery across Blood Brain Barrier. We focus on development and innovation of phage libraries and selection approaches, antibody...

Mathias holds a master’s in engineering in Molecular Biotechnology from Uppsala University and Ph.D. in molecular biology from Karolinska Institutet. He is a co-founder of the cord blood bank Cellaviva, established in 2014, a company that has evolved to NextCell Pharma AB which is developing stem...

BA diploma with focus on Production and Logistics from the University of Augsburg 3 Years Demand and Forecasting at Fujitsu Siemens Computer5 Years “Seihan” (fully integrated supply chain) Manager at Alpine Electronics7 Years Supply Chain Manager at Teva / Mepha Switzerland Since 2014 Head of...

Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on...

Matthew Turner is the Senior Director European Government Affairs Biosimilars at Fresenius Kabi. Following basic lab research in oncology, he joined the pharmaceutical industry 25 years ago.  His career started with the leadership of clinical trials evaluating new drug entities from phase 1 through ...

Thomas Valerius studied medicine at the University of Erlangen-Nürnberg, Germany. After his training in internal medicine, he specialized in hematology/oncology and rheumatology. Since May 2003, he has been working at the University in Kiel, Germany, where he currently is assistant professor at the ...

Faidra van der Wal has a rich experience in clinical operations and global trial management.She is a GCDO Trial leader within Janssen, were she has been accountable for phase 3 pivotal studies in immunology.Having worked prior for a CRO as well as for a small biotech company, she has built up a...

As the section leader for the Cytokines and Growth Factors Section, she is responsible for a number of diverse projects in these fields. These include preparation of World Health Organisation WHO international cytokine and growth factor standards and/or reference reagents, development and...

Stefan Weigand, PhD, has been with Roche since 2005. He is currently Head of Large Molecule Research (LMR) at Roche pRED, responsible for Roche’s industry-leading efforts in biologics from concept to clinic. Prior to taking on this role in 2015, Stefan was Head of Biochemical and Analytical...

Based in Cambridge, with a team of talented scientists, Dr Wilkinson is charged with the generation and delivery of novel candidate biotherapeutics. His team, uses the latest therapeutic strategies (incl. antibody and protein based platforms, oncolytic virotherapy and oligonucleotides) and is...

Paula Williamson is Professor of Biostatistics. She is Director of the MRC North West Hub for Trials Methodology Research (HTMR), Director of the Clinical Trials Research Centre (CTRC), and Head of the Department of Biostatistics at the University of Liverpool. Paula chairs the University of...

Florian M. Wurm, trained as Biologist/Molecular/Geneticis. His career involved academic and industrial work: Behringwerke AG, Marburg (1981-1984), Harvard Boston (1984-1985), Genentech Inc, San Francisco (1986-1995), Swiss Federal Institute of Technology, Lausanne (EPFL), (1995-2015), ExcellGene...

Jens Wuerthner is a physician scientist and currently holds the position of Head of Clinical Development – EU for ADC Therapeutics in Lausanne, Switzerland. He is a licensed physician in Germany, Switzerland and the UK and a fellow of the Faculty of Pharmaceutical Medicine, UK.Dr. Wuerthner...

Yingnan Zhang, Ph.D. in Biochemistry, is a Senior Scientific Manager at Genentech. She got her Ph.D in the field of enzymology and glycobiology from University of Miami, FL mentored by Dr. Keith Brew. She joined Genentech as a postdoc mentored by Dr. Sachdev Sidhu. She has been involved in many...

Stefan received his PhD in 2015 from the Technische Universität of Darmstadt, Germany, where he worked in the Group of Harald Kolmar in the field of protein engineering of non-canonical antibodies. During his PhD he spent some time at Scripps Institute, La Jolla (USA) working in the lab of Vaughn...